Home › Compare › KHDHF vs ABBV
KHDHF yields 20.53% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 2
Combined, KHDHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KHDHF + ABBV for your $10,000?
KHD Humboldt Wedag International AG provides engineering products and services for the cement industry. It operates through, Capex and Plant Services segments. The company engages in the process technology, design, engineering, project management, and supply of technology and equipment, such as grinding, pyro process, and system automation equipment. It offers grinding solutions, such as roller press grinding machines and separators; pyro lines or to retrofit select components comprise preheaters; calcined clay; Pyrorotor, a technology for processing alternative fuels; Pyroredox, a gasification reactor for reducing nitrogen oxides emissions; rotary kilns; calciners; firing systems; and clinker coolers. The company also provides automation solutions, which include burner management systems, cooler hydraulic control systems, ROLCOX to monitor, control, and analyze roller press operations for optimum grinding; ROMIX-c automatic raw meal control systems; and Scanex-IC that measures the temperature of areas smaller than a refractory brick. In addition, it offers training and education services for cement plant personnel, roller press scanner and roller refurbishment, consulting and assistance, audits and advisory, and maintenance support services, as well as e-learning programs about the pyro process; supplies spare and wear parts. KHD Humboldt Wedag International AG operates in North America, India, the Rest of Asia, China, the Middle East, the Rest of Europe, Russia, South America, Africa, Germany, and internationally. The company was founded in 1856 and is headquartered in Cologne, Germany. KHD Humboldt Wedag International AG is a subsidiary of AVIC International Engineering Holdings Pte. Ltd.
Full KHDHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.